Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer

PURPOSE: Despite curative resection, the 5-year survival for patients with resectable pancreatic cancer is less than 20%. Recurrence occurs both locally and at distant sites and effective multimodality adjuvant treatment is needed. MATERIALS AND METHODS: Patients with curatively resected stage IB-II...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyung-Hun, Chie, Eui Kyu, Im, Seock-Ah, Kim, Jee Hyun, Kwon, Jihyun, Han, Sae-Won, Oh, Do-Youn, Jang, Jin-Young, Kim, Jae-Sung, Kim, Tae-You, Bang, Yung-Jue, Kim, Sun Whe, Ha, Sung W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524012/
https://www.ncbi.nlm.nih.gov/pubmed/33421976
http://dx.doi.org/10.4143/crt.2020.928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524012/
https://www.ncbi.nlm.nih.gov/pubmed/33421976
http://dx.doi.org/10.4143/crt.2020.928

Ejemplares similares